WCM/EADO 2021 | Neoadjuvant IPI + NIVO in stage III melanoma: updates from OpACIN & OpACIN-neo
Christian Blank, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, provides an update on the Phase Ib OpACIN (NCT02437279) of neoadjuvant ipilimumab plus nivolumab (IPI + NIVO) in patients with stage III melanoma. Following a 4-year median follow-up, no patients with a pathologic response had relapsed and only early relapses were seen in non-responders. Similar results are observed in the subsequent Phase II OpACIN-neo study (NCT02977052), which evaluated three different dosing schedules of neoadjuvant IPI + NIVO in 86 patients with stage III melanoma. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.
Disclosures
Christian Blank, MD, PhD, has participated in an advisory role with BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre and Third Rock Ventures; has received research funding from BMS, Novartis and NanoString; is a stockholder in Uniti Cars; and is the Co-Founder of Immagene BV.
